An inducible Ku86-degrading serine protease in human cells  by Sallmyr, Annahita et al.
An inducible Ku86-degrading serine protease in human cells
Annahita Sallmyr, Liping Du, Anders Bredberg*
Department of Medical Microbiology, Lund University, Malmo¨ University Hospital, 205 02 Malmo¨, Sweden
Received 7 January 2002; received in revised form 2 September 2002; accepted 25 September 2002
Abstract
The Ku autoantigen has been implicated in a number of cellular functions including growth control, immunoglobulin gene rearrangement
and DNA repair. A variant truncated form of Ku86, with an apparent molecular weight of 70 kDa, has been reported to be present in many
human cell types. We have previously shown that the amount of variant Ku86 is strongly increased in human peripheral blood mononuclear
cells (PBMC) by storage of blood prior to isolation of the PBMC. In this study we report that formation of variant Ku86 in protein extracts is
mediated by an inducible trypsin-like serine protease with a higher concentration in the nuclear compartment, as compared with the
cytoplasm. However, experiments with SDS-PAGE assay of whole cells yielded no evidence of truncated Ku86, suggesting that the protease
is not active in intact cells, but is exerting a marked activity during the protein extraction procedure. Interestingly, the protease level became
markedly reduced upon transfer of the cells to growth medium. Protease induction did not correlate with apoptosis, necrotic cell death or with
signs of general proteolysis or cytotoxicity. Our findings have methodological implications for the interpretation of experimental Ku86 data,
and suggest that this protease may play a role for cellular regulation of Ku function.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Ku is a heterodimeric protein consisting of the Ku70 and
Ku86 subunits [1]. It is evolutionary well conserved from
yeast to mammals, fitting with the growing list of funda-
mental cellular processes reported to include a role of Ku.
Initially its influence on functions mediated by the DNA-
dependent protein kinase catalytic subunit (DNA-PKcs) such
as DNA double-strand break repair and V(D)J recombina-
tion was documented [1–3]. More recently, vital roles of Ku
have been reported in signal transduction [4], in DNA
replication [5], in cell cycle control [6,7] and cell growth
[7,8], and in telomere stability and cellular senescence [9–
11].
In most cell types studied, Ku has been interpreted to be
strictly composed of the two 70 kDa (Ku70) and 86 kDa
(Ku86) subunits, without any sign of alternative molecular
weight forms. However, in many cell types and tissues [12–
16] a fraction of Ku86 has been reported to appear as a
variant form with an apparent molecular weight of approx-
imately 70 kDa (designated in the present work as Ku86v).
In multiple myeloma bone marrow and HL-60 cells, the
presence of Ku86v was shown to correlate with an increased
sensitivity to gamma radiation [13,16].
Cellular control of Ku protein quantity and function has
been reported to occur at different levels. Proliferation was
shown to associate with intracellular redistribution and with
a marked increase in Ku mRNA [17,18], and the Ku protein
amount has been shown to increase in response to gamma
radiation [17,19,20]. Posttranslatory epitope modifications
and usage of a second promoter generating an extended
mRNA transcript have also been reported [15,18,21].
The present study was undertaken to document whether
the finding of Ku86v in peripheral blood mononuclear cells
(PBMC) [22] should be viewed as part of a general protein
disintegration in severely damaged cells, or if it rather
suggests an adaptive response in human cells responding
to certain environmental stimuli. The results indicate that
most, if not all, of the Ku86v appearing in PBMC protein
extracts are due to a nuclear serine protease with no signs of
0167-4889/02/$ - see front matter D 2002 Elsevier Science B.V. All rights reserved.
PII: S0167 -4889 (02 )00331 -2
Abbreviations: DNA-PKcs, DNA-dependent protein kinase catalytic
subunit; EMSA, electrophoretic mobility shift assay; PARP, poly(ADP)ri-
bose polymerase; PBMC, peripheral blood mononuclear cells; PMSF,
phenylmethylsulfonyl fluoride; Ku86v, variant form of Ku86
* Corresponding author. Tel.: +46-40-331350; fax: +46-40-336234.
E-mail address: anders.bredberg@mikrobiol.mas.lu.se (A. Bredberg).
www.bba-direct.com
Biochimica et Biophysica Acta 1593 (2002) 57–68
activity in intact cells, but causing rapid Ku86 degradation
during a protein extraction procedure. The activity of this
protease increases in PBMC during in vitro blood incuba-
tion and becomes clearly reduced upon transfer of the cells
to optimal growth conditions. The induction of this protease
is not associated with any signs of general proteolysis,
cytotoxicity, apoptosis or necrotic cell death. These findings
have implications for the interpretation of experimental
Ku86 data and consequently also for our understanding of
Ku function in human cells.
2. Materials and methods
2.1. Antibodies and protease inhibitors
Antibodies used were polyclonal goat anti-Ku-70 (SC-
1486) (reactive with a C-terminal epitope corresponding to
amino acids 590-608), anti-Ku-86 (SC-1484) (reactive with
a C-terminal epitope corresponding to amino acids 710–729)
and anti-DNA-PKcs (SC-1552) from Santa Cruz Biotech-
nology (Santa Cruz, CA); mouse monoclonals anti-Ku70
(K91620) (reactive with an N-terminal epitope correspond-
ing to amino acids 57–174) from BD Biosciences (San
Jose, CA), anti-Ku86 (P80, Ab-3) (clone S10B1) (reactive
with an N-terminal epitope corresponding to amino acids
8–221) and anti-tubulin (Ab-1, CP06) from Oncogene
(Cambridge, MA); anti-PARP (clone 4C10-5) was a mono-
clonal from PharMingen (San Diego, CA); polyclonal rabbit
anti-caspase-3 (AHP476) from Serotec (UK); human anti-
SSA/SSB serum from Immunoconcept (cat no. 7002) (Sac-
ramento, CA). Secondary HRP-conjugated antibodies were
from DAKO (Denmark). Phenylmethylsulfonyl fluoride
(PMSF), leupeptin, chicken trypsin-like protease inhibitor
and the soybean trypsin-like inhibitor were all from Sigma
(St. Louis, MO).
2.2. Cells and culture conditions
PBMC and HEp-2 cells were used as described [22]. The
long-term T cell cultures were used after 14–21 days of
growth in the presence of added IL-2 (Roche-Boehringer-
Mannheim, Germany). Flow cytometry characterization at
the end of the culture time, using monoclonal antibodies,
demonstrated a homogeneous population of >99% CD3+ (T
lymphocytes), < 1% CD19+ (B lymphocytes) and < 1%
CD14+ (monocytes) cells. Phytohaemagglutinine (PHA)
was from Sigma and used at 1 Ag/ml. The number of viable
(dye-excluding) and dead cells was counted manually using
trypan blue solution (Sigma) and light microscopy. Assay of
mitochondria respiratory capacity was by a colorimetric
tetrazolium-based MTT (Sigma) test [23]. Cells were then
cultivated in a 96-well microplate for 4 h in the presence of
500 Ag/ml MTT, and the amount of formazan salt produced
was then determined spectrophotometrically by its absorb-
ance at 570–590 nm.
2.3. Western blot
Crude extraction of cytoplasmic and nuclear proteins,
determination of protein concentration and immunoblotting
were performed using standard protocols as described by us
[22]. A mixture of protease inhibitors (Complete, Roche-
Boehringer-Mannheim; at 10%, v/v) (including serine, cys-
teine and metalloproteases according to the manufacturer)
was used for the protein extraction, unless otherwise indi-
cated. In brief, the cytoplasmic and nuclear protein extracts
(10 and 5 Ag, respectively) were pre-treated for 10 min at 70
jC in gel loading buffer containing detergent and reducing
agent before loading onto NuPAGE 7 or 10% pre-cast gels.
After electroblotting, the membranes were incubated with
the indicated primary antibodies in a blocking buffer and
with a secondary HRP-conjugated antibody. The blots were
developed using the enhanced chemiluminescence method
(ECL from Amersham-Pharmacia, UK). The relative inten-
sity of the truncated Ku86 band was determined by exami-
nation of X-ray film in a BioRad Personal Molecular Imager
FX and with the Quantity One software. For the whole-cell
lysis experiments, 5 105 cells were lysed at 95 jC for 10
min in gel loading buffer prior to the electrophoresis.
2.4. Flow cytometry
A Coulter Epics XL-MCL flow cytometer (Coulter, FL)
was used, with filters detecting emission at 515–545 nm (for
FITC) and 565–595 nm (for propidium iodide). Background
autoflourescence was monitored for each sample by analy-
sing unlabelled cells. Apoptosis was measured as described
[24]. At least 3000 events were scored. FITC-labelled
Annexin V was from Alexis (Switzerland) and PharMingen.
2.5. Electrophoretic mobility shift assay (EMSA)
Preparation of the radiolabelled DNA probe was as
follows: A double stranded 25-mer DNA was prepared by
two complementary oligonucleotides (5V-ATGGGCAGGT-
CACGTGGTTCCAGGC-3Vand 5V-GCCTGGAACCACGT-
GACCTGCCCAT-3V). The two oligonucleotides (100 ng)
were end-labelled with 1.2-Al T4 polynucleotide kinase (8
U/Al) in the presence of 3-Al [g 32P] ATP 5000 Ci/mmol
(Amersham) for 10 min at 37 jC. The reaction was then
stopped by incubation at 95 jC for 5 min and subsequently
annealed at room temperature for 2 h. A Pharmacia G25
column was used to purify the probe from free isotope. The
activity was adjusted to 50000 cpm/Al. A master-mix was
prepared by adding 10-Al 2 binding buffer (40 mM
HEPES pH 7.3, 100 mM KCl, 6 mM MgCl2, 2 mM EDTA,
16% glycerine, 10% BM Complete protease inhibitor and 5
Al of 2% Na-azide), 2-Al 100 mM DTT and 1 Al of radio-
labelled DNA (50–100 ng, 50000 cpm/Al). The master-mix
was incubated on ice for 20 min with 2 Ag of nuclear extract
in the presence of 0.3-Ag closed circular DNA of a pGEM
plasmid (Promega, WI) as a nonspecific competitor (yield-
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ing 10 molar excess and 1000 weight excess). In some
experiments cold probe was used as specific competitor (at
50 molar excess). All gel shift bands were lost in the
presence of 50 molar excess unlabelled linear DNA
fragment probe. A 5% native polyacrylamide gel was pre-
run for 30 min before loading the samples. After electro-
phoresis the gel was dried between two clear cellophane
paper sheets overnight and exposed to X-ray film at  70
jC for 3 days. In the super-shift experiments, the indicated
antibody was added to the binding mixture followed by
another incubation on ice for 30 min prior to the gel
electrophoresis.
2.6. Combined EMSA and immunoblot
EMSA was performed as in Section 2.5, with some
modifications. Nuclear protein, 5 Ag, was loaded in duplicate
onto a 6% DNA retardation pre-cast gel (Novex). One part of
the gel was dried between two clear cellophane papers as in
Section 2.5. The other part of the gel was blotted onto a
PVDF membrane using a denaturing pH 8.0 transfer buffer
containing 0.5% SDS, 20% methanol, 20 mM Tris and 150
mM glycine. Incubation of the membrane with the indicated
antibodies was then done as in Section 2.3.
3. Results
3.1. Induction of a Ku86-degrading protease in human
PBMC, with its highest concentration in the cell nucleus
In order to document the general occurrence of the Ku86
degradation in human PBMC previously reported by us
[22], initial experiments were made with an unspecified
period of time (e.g. less than 2 days) for the blood
incubation before isolation of PBMC and protein extraction.
Results from five representative individuals (P1–P5) are
presented in Fig. 1A and B, demonstrating a great variation
between blood donors in Ku86 degradation. The relative
intensity (i.e. compared to the sum of full-length Ku86 plus
Ku86v, but without consideration of the lower molecular
weight bands observed in some samples indicating highly
degraded Ku86) of the Ku86v band was determined using
Fig. 1. Formation of Ku86 variant form (Ku86v) in human PBMC. Blood
was incubated at room temperature for an unspecified time period (A, B) or
for the indicated times (0–48 h) (D, E) before PBMC were isolated. Protein
extracts were then separated by SDS-PAGE and immunoblotted with an
antibody to an N-terminal Ku86 epitope (A, C, D), C-terminal Ku86 (B),
tubulin (E, right panel) or with a human anti-SSA/SSB serum (E, left panel).
P1–P5 (A, B), lanes 1–8 for T cells (i.e. long-term IL-2 dependent T
lymphocyte cultures) (C) and PBMC1–3 (D) represent different healthy
blood donors. Positions of molecular weight standards are shown on the
right. The arrows indicate the positions of full-length Ku86 and Ku86v.
The relative intensity of the Ku86v band (compared to full-length Ku86
plus the Ku86v) was determined using imaging equipment.
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imaging equipment, and is indicated as percentage in the
figures. A higher fraction of Ku86v is found in the nuclear
extract, as compared with the cytoplasm, in all cell types
studied by us, including those shown in Fig. 1A. Moreover,
the Ku86v in all cases seems to result from a C-terminal
cleavage, since the C-terminal anti-Ku86 antibody was
found to be able to detect only intact nontruncated Ku86
protein, as judged by the close correlation between the C-
Fig. 2. Ku86 degradation is mediated by an inducible trypsin-like serine protease. PBMC were isolated after blood incubation for the indicated times (0–48 h).
Equal amounts of two different nuclear protein extracts (using the standard protocol with 10% BM protease inhibitors) were then mixed, incubated at 37 jC for
the indicated times (5 min–8 h), and then analysed by immunoblotting using the ab to N-terminal Ku86 (A). Additional protease inhibitors were added to the
extract mixes during a 30-min coincubation: no addition (i.e. BM at 10%) or leupeptine (100 AM) (B); BM (25%, indicated by the arrow), PMSF (3 mM),
chicken eggwhite trypsin-like protease inhibitor (chick, 100 AM), soybean trypsin-like protease inhibitor (soy, 100 AM) (C). Co-incubation with a higher-
activity protease extract was also made to test the inhibitory effect of the soybean inhibitor (at 100 AM) (D). For the immunoblotting the antibody to N-
terminal Ku86 was used. Results are from single gel experiments; the gel has been cut to improve data presentation by reordering the lanes.
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terminal antibody single band (Fig. 1B) and the N-terminal
antibody band corresponding to full-length Ku86 (upper
band in Fig. 1A). With the resolution of the present
methodology, the Ku86v shows up as either a single band
(Fig. 1C and D), or as a doublet band (Fig. 1A), as
previously found by other workers [16,25]. A fraction of the
total cellular content of Ku86 was present as Ku86v in all of
the cell types studied by us, including PBMC from more
Fig. 2 (continued).
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than 30 healthy blood donors, IL2-dependent long-term T
lymphocyte cultures derived from eight blood donors (Fig.
1C), and in lymphoid and epithelial lines (data not shown).
The inter-individual variation in Ku86 degradation was
found to be strongly influenced by the time of blood
incubation, although Ku86v could be demonstrated for most
of the blood donors also in unincubated blood samples (Fig.
1D). Enhancement of Ku86 cleavage due to blood incuba-
tion was found to be a general phenomenon in PBMC,
occurring with all blood donors tested by us. Furthermore,
this inducibility could be documented in both cytoplasmic
and nuclear protein extracts (Fig. 1D, right panel).
To determine whether a general protein degradation
accompanies the formation of Ku86v, immunoblotting anal-
ysis of the RNA-associated multiprotein SS-A/SS-B autoan-
tigen and tubulin was performed, providing no evidence of
alteration in band configuration in nuclear protein extracts
(Fig. 1E, left panel, SS-A/SS-B), or in the cytoplasmic
extracts (Fig. 1E, right panel, tubulin). Thus, the protease
activity appears to be relatively specific for Ku86 protein.
Tubulin immunoreactivity was usually completely lacking in
nuclear extracts, verifying that the protein extraction protocol
yields a nuclear preparation containing only nuclear compo-
nents. No Ku70 degradation products were observed with the
presently employed antibody in any of the cell types studied
by us, including PBMC and cell lines, although a decrease in
the intensity of the Ku70 band was seen with PBMC from
some of the incubated blood samples (data not shown).
3.2. Characterization of a protease responsible for Ku86
degradation
To verify the existence of a Ku86-degrading protease
activity, PBMC 0-h containing predominantly full-length
Ku86 (Fig. 2A, lane 1) and 48-h nuclear protein extracts
with Ku86v (Fig. 2A, lane 2) were mixed (lane 3). Within as
little as 5 min of 37 jC coincubation time, truncation of
Ku86 could be demonstrated (lane 4). The additional
coincubation time points (1–8 h) served to indicate that
no further degradation of the Ku86v into highly degraded
Ku86 could be seen in these experiments (lanes 5–7). A
parallel 8-h incubation of the PBMC 0-h extract caused only
minor truncation of Ku86 (lane 8).
In order to characterize the protease responsible for the
degradation of Ku86, the effect of various protease inhibitors
was examined including leupeptin and PMSF (both being
inhibitors of some serine and cysteine proteases), a commer-
cially available cocktail of protease inhibitors (here called
BM, containing unspecified inhibitors of serine, cysteine and
metalloproteases), and two trypsin-like serine protease inhib-
itors (from chicken eggwhite and soybean). Nuclear protein
was extracted from PBMC 0-, 24- and 48-h in the presence of
either 10% BM (i.e. our standard protocol for protein extrac-
tion) or leupeptin as protease inhibitor. Leupeptin was first
tested, due to its reported capacity to fully inhibit (at 5 AM)
the Ku86 truncation occurring in senescing human fibroblasts
[14]. However, extraction in the presence of a high concen-
tration (100 AM) of leupeptin was found to lead to even
slightly more truncation of the full-length Ku86, as compared
with the BM standard protocol (Fig. 2B). Therefore, in
contrast to senescing human fibroblasts, the Ku86 truncating
protease of PBMC is not inhibited by leupeptin. Besides the
band corresponding to Ku86v, bands < 70 kDa indicating
highly degraded Ku86 were observed with a slightly
increased intensity in the 48-h extract, indicating proteolysis
activity beyond a single C-terminal cleavage site (Fig. 2B).
Another extract mixing experiment was then set up in the
presence of a panel of protease inhibitors. Full-length Ku86
was degraded in the presence of the PBMC 48-h extract,
even when supplemented with additional BM (25%) (Fig.
2C, lane 4), PMSF (lane 5) or a chicken eggwhite trypsin
inhibitor (lane 6). Both the Ku86v band and a < 40 kDa
band (most pronounced for PMSF) provided evidence for
this proteolysis. However, the chicken egg white inhibitor
protected a fraction of the Ku86 protein from degradation
(lane 6). In contrast, in the presence of soybean trypsin
inhibitor no protease activity was detected; the banding
pattern remained the same as for the non-incubated extract
mix (lanes 3 and 7). In order to verify this inhibitory
influence of the soybean inhibitor, a PBMC 48-h nuclear
Fig. 3. SDS-PAGE assay of whole cells suggests lack of Ku86 degradation in intact cells. PBMC were isolated from blood incubated for 0 and 48 h, lysed in the
denaturing and reducing gel loading buffer for 10 min at 95 jC, and then immediately subjected to SDS-PAGE. Immunoblotting was made with N-terminal
anti-Ku86.
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protein extract showing no intact Ku86 and no Ku86v,
suggesting a very pronounced protease activity, was tested
(Fig. 2D). In the absence of soybean protease inhibitor a 30-
min coincubation period led to degradation of most full-
length Ku86, even beyond the Ku86v form and presenting a
< 40-kDa band (some reactive degradation products prob-
ably were electrophoresed out of the gel) (Fig. 2D, lane 4).
An unusual banding pattern was seen in lane 4, with some
remaining intact Ku86 but no sign of Ku86v, probably
reflecting an unusually high content of Ku86-degrading
Fig. 4. Ku function analysis. Nuclear protein was extracted from PBMC isolated from blood incubated for the indicated times (0–48 h). Immunoblotting was
made with anti-DNA-PKcs (A). In order to determine the binding of Ku86 to free DNA ends, a
32P-labelled linear DNA fragment was incubated with PBMC
nuclear protein extract, followed by addition of an antibody as indicated, and subjected to native PAGE. The free probe is located just below the depicted gel.
The result is from a single gel experiment; the gel has been cut to improve data presentation by reordering the lanes (B). In a separate experiment, a duplicate
EMSA gel was used for gel shift analysis and immunoblotting, to determine the presence of Ku in the gel shift bands (C). The left panel shows a conventional
Western blot using PBMC nuclear extracts and N-terminal anti-Ku86. The second panel from left shows EMSA, and the two right panels the immunoreactivity
of the blotted duplicate EMSA gel using C-terminal anti-Ku70 and N-terminal anti-Ku86.
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protease in this PBMC 48-h nuclear extract. However, the
presence of the soybean trypsin inhibitor blocked the
degradation of full-length Ku86 in a concentration-depend-
ent manner (result not shown) with complete inhibition of
proteolysis apparent at a concentration of 100 AM (Fig. 2D,
lane 5). Taken together, our data suggest that a trypsin-like
serine protease responsible for Ku86 degradation is being
localized mainly to the nucleus and degrades Ku86 sequen-
tially into 70 and < 40 kDa fragments.
3.3. SDS-PAGE assay of whole cells suggests lack of Ku86
degradation in intact cells
The documentation of a strong protease activity in PBMC
48-h extracts, leading to significant Ku86 degradation within
as little as 5 min in the coincubation experiments (Fig. 2A,
lane 4), raised the question whether the observations of
Ku86v in protein extracts reflect the action of this protease
only upon experimental procedures or in intact cells. In order
to minimize opportunity for this protease to exert its function,
experiments were performed omitting the protein extraction
procedure (Fig. 3). PBMC were lysed at 95 jC for 10 min in
SDS-PAGE gel loading denaturing buffer, immediately fol-
lowed by loading onto the gel. For most of the blood donors
full-length Ku86 was seen irrespective of blood incubation,
with no band located at the expected position of the Ku86v
form (Fig. 3). Our collected data suggest that this experi-
mental protocol with whole-cell lysis is associated with a
large variation in band intensity, as may be expected from
interference with protein mobility during an electrophoresis
of a sample containing all cellular components. Therefore, the
smear pattern seen in the 48-h lane 2 of Fig. 3 was not
considered to reflect intracellular Ku degradation. This result
indicates that the Ku86-degrading protease is kept in an
inactive state within cells, and triggered to become active
during a protein extraction procedure.
3.4. Functional analysis of Ku86v
C-terminally truncated Ku86 has been shown by others
[26] to lack DNA-PKcs-activating capacity. Accordingly, we
observed a strong DNA-dependent phosphorylation of a p53
peptide with PBMC 0-h extracts, indicating the presence of
Ku protein leading to DNA-PKcs activity, whereas no such
phosphorylating function could be found in PBMC 24-h and
48-h extracts (results not shown). Interestingly, in parallel
with the appearance of Ku86v, there is a loss of immunor-
eactive DNA-PKcs during blood incubation (Fig. 4A). There-
fore, it remains an open-ended question whether the Ku86v
found in PBMC can mediate DNA-dependent phosphorylat-
ing activity.
The DNA end-binding activity of Ku protein was also
analysed. PBMC nuclear extracts were incubated with a 32P-
end-labelled 25-bp double-stranded linear DNA fragment
assumed to permit the binding of one Ku molecule [16].
This reaction mixture was subjected to native polyacryla-
mide gel electrophoresis. A clear gel shift was observed
with a PBMC 0-h protein extract (Fig. 4B, lane 2). The
upper gel shift band is super-shifted by C-terminal anti-
Ku86 (Fig. 4B, lane 4), indicating the presence of full-length
Ku86. C-terminal anti-Ku70 caused a relatively weak super-
shift with the PBMC 0-h extract (lane 6). PBMC 24-h
protein extract produced only the lower gel shift band (lane
3), with no sign of super-shift using these antibodies (lanes
5 and 7). There was no super-shift with N-terminal anti-
Ku86, with any of the extracts (results not shown), provid-
ing no data on whether Ku86v is capable of binding to
DNA.
To get more detailed information on Ku binding to DNA,
the EMSA (native polyacrylamide) gel was immunoblotted.
Nuclear extracts were analysed with Western blot showing
intact Ku86 (PBMC 0-h) or predominantly Ku86v (PBMC
48-h) (left panel, Fig. 4C), and also with EMSA showing
two prominent gel shift bands (PBMC 0-h) or a weaker
lower band (PBMC 48-h) (second panel from left). Western
blot performed with anti-Ku70 (both N- and C-terminal,
respectively) showed full-length Ku70 at both 0 and 48 h,
with no indication of Ku70 degradation (not shown). A
duplicate EMSA gel was blotted under denaturing condi-
tions onto a PVDF membrane, and then analysed for
immunoreactivity. Both anti-Ku70 (N- and C-terminal,
respectively) and anti-Ku86 (N-terminal, detecting the
Ku86v form) formed a single band located at a position
corresponding to the upper gel shift band, but gave no signs
of Ku protein present in the PBMC 0-h lower gel shift band
or at any PBMC 48-h location (two right panels).
In summary, our DNA-binding results are in line with a
prevailing view that heterodimeric Ku70/Ku86 binds to
DNA ends, but that neither subunit alone can bind DNA
effectively [1,3]. Furthermore, the lack of Ku-related gel
shift reactivity with the PBMC 48-h extract suggests that the
truncated Ku86v form does not bind to DNA.
3.5. Characterization of cell viability associated with
formation of the Ku86-degrading protease
A number of experiments were performed in search of a
correlation between signs of toxicity and formation of the
Ku86-degrading protease, including a general cytotoxic
influence, caspase activation and membrane reorganisation
Table 1
Lack of cytotoxicity signs during the induction of Ku86-truncating protease
activitya
Blood incubation
0 h 24 h
Ku86v in cytoplasmic extract < 5 80
Ku86v in nuclear extract 40 >95
Trypan blue dye excluding PBMC (%) >95 >95
Mitochondrial respiratory activity in
PBMC (MTT assay)
pos pos
a Results from representative experiments are shown.
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Fig. 5. No sign of apoptosis during induction of the Ku86-degrading protease. PBMCwere isolated after blood incubation for the indicated times (0–72 h). SDS-
PAGE assay of whole cells lysed in the gel loading buffer (A, left panel) and nuclear protein extract (A, right panel) was followed by immunoblotting with anti-
PARP (the arrow indicates the position of full-length PARP). Procaspase-3 and its protease-active caspase-3 derivative were also analysed by immunoblotting of
PBMC nuclear and cytoplasmic protein extracts obtained from two blood donors, P1 and P2 (B). Isolated PBMCwere also subjected to annexin Vanalysis using
flow cytometry (C). Annexin V-positive but propidium iodide (PI)-negative cells are considered to be in apoptosis, whereas double-positive cells are regarded as
necrotic (or late apoptotic). Staurosporine (0.5 AM for 72 h) was used as a positive control for apoptosis induction.
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characteristic of apoptosis. PBMC from incubated blood
displaying an enhanced fraction of Ku86v did not present
any strong signs of decreased viability, as assessed by trypan
blue dye exclusion and by mitochondria respiratory capacity
(Table 1). The caspase-mediated site-specific cleavage of
poly(ADP)ribose polymerase (PARP) is often used as a
marker of caspase activation and early apoptosis. Whole
cells as well as nuclear protein extracts from 0 and 24 h were
subjected to immunoblotting with anti-PARP. The 113-kDa
full-length form was found to be cleaved in the incubated
samples, however, without any evidence of caspase activity
(expected to yield specifically PARP 89- and 24-kDa frag-
ments) [27,28] (Fig. 5A). The similar banding pattern was
seen in both extracted protein and in whole cells, indicating
that the PARP degradation occurs in intact cells, and possibly
also during the protein extraction procedure. In agreement
with the PARP results, analysis of caspase-3 in protein
extracts from incubated PBMC (24 h) showed a single band
corresponding to the 32-kDa procaspase form in both cyto-
plasm and nucleus (10 Ag), without signs of activated
caspase-3 (17 kDa) (Fig. 5B). The same membrane showed
the presence of Ku86v in the nuclear extract and also of
tubulin in the cytoplasmic extract (Fig. 5B).
The influence of blood incubation on another marker of
PBMC apoptosis, the binding of Annexin V to cell mem-
brane phosphatidylserine, was also investigated. Flow
cytometry showed a minor fraction of Annexin V-positive
PBMC, with no apparent difference between cells isolated
from freshly collected blood (0.3% apoptosis, Fig. 5C,
PBMC 0 h, lower right quadrant) or after 72 h of blood
incubation (0.5% apoptosis, Fig. 5C, PBMC 72-h). In
addition, there was no increase of necrosis in PBMC 72-h,
as measured by binding of both propidium iodide and
Annexin V (Fig. 5C, PBMC 0-h and 72-h, upper right
quadrants). The ability of the assay to detect apoptosis and
necrosis was verified by the incubation of PBMC 0-h in the
presence of staurosporine for 72 h (0.5 AM), causing a
marked apoptosis reaction (16.8% Annexin V-positive), and
also necrosis in a smaller fraction (5.0% of PBMC were
positive for both Annexin Vand propidium iodide) (Fig. 5C,
PBMC 72-h staurosporine). Thus, our collected data indi-
cate no correlation between cell death and the formation of
the Ku86-degrading protease.
3.6. The induction of Ku86-degrading protease can be
reversed
Ku86 protein participates in a number of cellular pro-
cesses and its function is likely to be regulated in response
to various physiological conditions. In order to collect
evidence compatible with a physiological role of the
Ku86-degrading protease, reversibility of the protease
induction was investigated. Blood was incubated in vitro
for 0–48 h, PBMC were isolated, mitogen-stimulated with
PHA and then cultivated in growth medium. After 3 days of
optimal growth conditions, cytoplasmic and nuclear protein
was extracted and subjected to SDS-PAGE. As expected,
the fraction of Ku86v was seen to increase in the nuclear
extracts of uncultured PBMC from 0 to 48 h (Fig. 6, lanes 1,
4 and 7). A clearly higher fraction of full-length Ku86 was
observed in extracts from cells kept in culture medium for 3
days, as compared with uncultured cells (lanes 2, 3, 5, 6, 8
and 9). This effect was slightly enhanced in the presence of
PHA (lanes 3, 6, and 9). These results indicate that trans-
ferring PBMC to growth medium decreases the level of this
Ku86-degrading protease. The same pattern of reversed
protease concentration was found in cytoplasmic extracts,
although with less pronounced Ku86 degradation (data not
shown).
4. Discussion
A truncated and functionally restricted Ku86v form has
been reported to be present, at varying levels, in many
human cell types. Our present findings suggest this Ku86v
to be formed by an inducible and relatively selective
trypsin-like serine protease, localized mainly to the nucleus
and using the C-terminal region of Ku86 as a substrate.
Although strong protease activity was observed in cellular
protein extracts, leading to formation of Ku86v, we could
not document any protease activity leading to Ku86 degra-
dation in intact cells. Then, what significance can be
ascribed to our findings?
There are a number of observations suggesting that
Ku86v does indeed originate from the proteolytic degrada-
tion of full-length Ku86. First, although a posttranslatory
epitope modification might block access to Ku86 of a C-
terminal-binding antibody, this would not be expected to
yield the observed increase in electrophoretic mobility of
Ku86v reflecting physical shortening of Ku86. Second,
there were no signs of newly synthesized Ku86v molecules
being added to the pre-existing pool of full-length Ku86,
Fig. 6. The induction of the Ku86-degrading protease in PBMC can be re-
versed. PBMC were isolated from blood incubated for 0–48 h, and then
cultivated for 72 h in the presence or absence of PHA, followed by protein
extraction, SDS-PAGE and immunoblotting using N-terminal anti-Ku86.
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since in many experiments the appearance of Ku86v is
proportionally accompanied by a loss of intact Ku86.
Interestingly, the protease causing formation of Ku86v
seems to be different from that of ageing human fibroblasts
reported to be inhibited by leupeptin [14]. However, the
soybean trypsin inhibitor was not included in that study, and
the divergent results may therefore possibly be due to
different conditions of the employed protease assay.
Analysis of trypan blue dye exclusion, Annexin V bind-
ing, mitochondrial respiration and caspase function showed
that the Ku86-degrading protease does not reflect a general
breakdown of cellular homeostasis. On the contrary, the
collected data indicate a relatively limited proteolysis: (i)
immunoblotting showed several proteins including cytoske-
leton and ribonucleoprotein particle (RNP) components to
be unaffected, whereas some large proteins including DNA-
PKcs and PARP were degraded; (ii) total cell protein
Coomassie blue staining revealed most proteins to be kept
intact, whereas some protein bands in the high molecular
weight range were lost, indicating action on a minor subset
of the cellular proteins (data not shown).
Reports by others have suggested a physiological role of
Ku86 mutants [29–31], and some of our findings are
suggestive of a potential for this protease to regulate Ku
function in human cells: (i) protease induction is seen in
fully viable and non-apoptotic cells; (ii) protease activity is
decreasing upon transfer of cells to optimal growth con-
ditions; (iii) the C-terminal shortening of Ku86 is most
probably associated with a loss of DNA-binding capacity.
The plethora of seemingly unrelated functions assigned to
Ku makes it tempting to speculate that there might be a
basic cellular condition including some demand for DNA
modification under the influence of full-length Ku86,
whereas under specific growth or signalling conditions the
cell favours the presence of Ku86v.
The present findings have a general relevance for the
interpretation of experimental results obtained in Ku protein
studies. By paying strict attention to minimize the extent of
in vitro incubation, it has been possible to document that in
human B lymphocytes full-length Ku86 retains its DNA-
PKcs-activating function [22,32]. These findings are in
contrast with published data on human B lymphocytes
showing variant Ku86 [25] and an enhanced sensitivity to
gamma radiation [33]; in the light of the present observa-
tions, these conflicting data may be due to experimental
conditions favouring the induction of a Ku86-degrading
protease. In addition, discrepancies among a number of
studies on the intracellular distribution of Ku protein
[6,18,34] may at least in part be explained by induction of
a Ku86-degrading protease, together with the common
usage of antibodies unable to bind to Ku86v epitopes. As
an example, in one of these studies [18], fixation-dependent
results were described with an antibody recognizing the
610–705 C-terminal segment unlikely to detect Ku86v.
Regarding a reported Ku86 epitope modification during
viral infection [15], it seems to be an open-ended question
whether the observed change in Ku immunoreactivity may
have been caused by an inducible proteolytic activity.
In conclusion, the present work emphasizes the need to
pay attention to significant methodological problems and
pitfalls in assessing Ku86. In addition, it describes an
inducible protease with a potential to play a role in the
regulation of Ku function in human cells.
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